COMPANY

Now is the time for peptide therapeutics

At Peptilogics, we are ushering in a new era of peptide therapeutics with biology- and data-driven scalable design.

Why Peptides

Peptides are Nature’s Intended Blockbusters
Peptide medicines have the potential to target previously hard-to-address disease areas and overcome barriers that occur in traditional drug development. They are an established modality that can combine the drug-like characteristics of small molecules with the specificity of biologics. Despite a long history, the field of peptide therapy is ripe for innovation.

Through advances in peptide synthesis technology and computational design, we can move beyond broad, random screening to chart the universe of functional peptides and design novel therapeutics.

Our Purpose
Revolutionize the discovery process for novel peptide therapeutics to help patients with serious and life-threatening diseases.

Our Approach

Peptilogics was founded in 2013 to advance novel peptide therapeutics and harness the power of a design-based approach to drug discovery.

Our approach bridges three components to drive discovery: peptide R&D, proprietary artificial intelligence technologies and high-performance computing capabilities. Our computational drug design platform connects and extracts insights from diverse biomedical data, allowing us to unlock a new universe of unexplored, novel peptides with powerful applications. Learn more about our Platform.

Team

Jonathan Steckbeck, PhD, MBA

CEO & Founder

Albert Fonticiella MBA, SHRM-SCP

VP of People

Jodie Gillon

SVP Corporate Affairs & Patient Advocacy

David Huang, JD, MD, PhD

SVP & Chief Medical Officer

Steve Kulp

VP of Operations

Francis Lee

SVP, Platform & Technology

Marc Lesnick, PhD

SVP, Regulatory and Quality

Nicholas Nystrom, PhD

Chief Technology Officer

Nick Pachuda, DPM

SVP, Portfolio Strategy & Development

Jonathan Steckbeck, PhD, MBA

CEO & Founder

Albert Fonticiella MBA, SHRM-SCP

VP of People

Jodie Gillon

SVP Corporate Affairs & Patient Advocacy

Steve Kulp

VP of Operations

Francis Lee

SVP, Platform & Technology

Nicholas Nystrom, PhD

Chief Technology Officer

David Huang, JD, MD, PhD

SVP & Chief Medical Officer

Marc Lesnick, PhD

SVP, Regulatory and Quality

Nick Pachuda, DPM

SVP, Portfolio Strategy & Development

Board

Dietrich Stephan, PhD

Chairman

Jonathan Steckbeck, PhD, MBA

President, CEO & Founder
Peptilogics

Jason Camm

Managing Director & Chief Medical Officer
Thiel Capital

Fabian Hansen

Director
PreSight Capital

Hannes Holste

Director
Thiel Capital

Investors

Global investment firm of Peter Thiel

Europe and US-based life science & technology fund

Leading international technology investment fund

World’s leading anti-infectives fund

Advisors

Thomas K. Fehring, MD

Clinical Advisor, Surgery

Javad Parvizi, MD, FRCS

Clinical Advisor, Orthopedics

Craig Della Valle, MD

Clinical Advisor, Orthopedics

Kenneth Urish, MD, PhD

Clinical Advisor, PJI

Matthew Dietz, MD

Clinical Advisor, Orthopedics

Neel Shah, MD

ID Physician, PJI Focus

George Church, PhD

Scientific & Computational Biology

RIck Oleson, DSC

Drug Development

Dean Shinabarger, PhD

Microbiology

Robert F. Murphy, PhD

Computational Biology,
AI Machine Learning

Parviz Ghahramani, PhD, PharmD, MBA

Drug Development
& Pharmacology

Nani Kadrichu, PhD

Pharmaceutical Inhalation

Partners

We are always speaking with innovative partners to help translate great science into important medicines.

Email us at partners@peptilogics.com to explore partnership opportunities with Peptilogics.